Antitumor activity of 2'-deoxy-2'-methylidenecytidine, a new 2'-deoxycytidine derivative. 1991

K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd., Saitama, Japan.

The antitumor activity of 2'-deoxy-2'-methylidenecytidine (DMDC), an inhibitor of DNA synthesis, was examined and compared with that of 1-beta-D-arabinofuranosylcytosine (ara-C) against various murine tumors and human tumor xenografts. Against P388 murine leukemia, repeated treatments of DMDC were more effective than its single administration. Interestingly, DMDC was effective against colon 26 murine carcinoma, M5076 murine reticulum cell sarcoma, LX-1 human lung cancer xenograft, and SK-Mel-28 human melanoma xenograft, which are less sensitive or refractory to ara-C, while DMDC was not more potent against murine leukemias P388 and L1210 than ara-C. The in vitro cytotoxic effects of DMDC and ara-C against L1210 leukemia cells were prevented dose dependently by deoxycytidine, suggesting that DMDC, like ara-C, may require phosphorylation by deoxycytidine kinase for antitumor activity. DMDC was effective against human and murine experimental tumor models, especially nonleukemic tumors refractory to ara-C, suggesting that DMDC will be a promising agent for the treatment of cancer.

UI MeSH Term Description Entries
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
June 2000, Clinical pharmacokinetics,
K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
October 1996, Biological & pharmaceutical bulletin,
K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
February 1998, Clinical cancer research : an official journal of the American Association for Cancer Research,
K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
November 2000, European journal of clinical pharmacology,
K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
January 1996, Cancer chemotherapy and pharmacology,
K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
July 1985, Japanese journal of cancer research : Gann,
K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
July 1990, Cancer research,
K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
June 2000, Clinical cancer research : an official journal of the American Association for Cancer Research,
K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
February 1991, Journal of medicinal chemistry,
K Yamagami, and A Fujii, and M Arita, and T Okumoto, and S Sakata, and A Matsuda, and T Ueda, and T Sasaki
October 2007, The Journal of toxicological sciences,
Copied contents to your clipboard!